1. Home
  2. LANV vs MOLN Comparison

LANV vs MOLN Comparison

Compare LANV & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lanvin Group Holdings Limited

LANV

Lanvin Group Holdings Limited

HOLD

Current Price

$0.54

Market Cap

115.8M

Sector

Finance

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$2.53

Market Cap

103.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LANV
MOLN
Founded
2015
2004
Country
China
Switzerland
Employees
N/A
N/A
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
115.8M
103.5M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
LANV
MOLN
Price
$0.54
$2.53
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $9.97
AVG Volume (30 Days)
★ 9.9K
1.7K
Earning Date
08-26-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$2.63
52 Week High
$2.31
$5.36

Technical Indicators

Market Signals
Indicator
LANV
MOLN
Relative Strength Index (RSI) 19.75 26.89
Support Level N/A N/A
Resistance Level $1.13 $4.21
Average True Range (ATR) 0.05 0.12
MACD -0.01 -0.06
Stochastic Oscillator 19.28 0.41

Price Performance

Historical Comparison
LANV
MOLN

About LANV Lanvin Group Holdings Limited

Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the St. John segment.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: